SI-BONE raises 2026 guidance after 15% revenue growth in Q2
SI-BONE reported second-quarter 2026 worldwide revenue of $56.0 million, a 15.2% increase on the prior-year period, and raised its full-year revenue guidance to a range of $231 million to $233 million, implying annual growth of roughly 15% to 16%. The NASDAQ-listed spinal implant company also posted positive adjusted EBITDA of $2.8 million for the quarter, a near-threefold improvement on the $1.0 million recorded in Q2 2025.
U.S. revenue of $53.2 million accounted for the bulk of the top line, growing 14.7% year-on-year on the back of 14.9% growth in procedure volume. The active U.S. physician base expanded 19% to 1,715 over the same period, a metric the company highlighted as evidence of platform adoption rather than purely pricing-led growth. International revenue of $2.8 million grew 25.9%, with management attributing the outperformance to early commercial traction from the iFuse TORQ and iFuse TORQ TNT product lines.
Regulatory and reimbursement backdrop
SI-BONE submitted a 510(k) application in June for what it described as its third breakthrough-device-designated product targeting one of the largest unmet needs in spine surgery. The company did not name the indication in the release, but said it expects to launch the device in the fourth quarter of 2026. Breakthrough Device designation from the US Food and Drug Administration does not guarantee clearance, but it provides an interactive review pathway that can materially shorten the time from submission to decision.
On the reimbursement side, the Centers for Medicare and Medicaid Services finalised a new MS-DRG family that will deliver higher inpatient payments for complex spinal fusion procedures incorporating SI-BONE's iFuse Bedrock Granite implant, effective 1 October 2026. Favourable coding changes of this kind can act as a meaningful commercial catalyst for procedural medtech companies, reducing the economic friction that hospital systems and surgeons face when adopting newer implant systems.
Chief executive Laura Francis said the combination of a new product launch, an improved reimbursement environment, and an expanding commercial footprint positioned the company to "enter our next phase of strong, sustainable multi-year revenue growth."
Market context and competitive position
The sacroiliac joint and spinopelvic fixation market has attracted increasing attention from larger orthopaedic and spine-surgery platforms over the past several years, including participants with substantially greater commercial infrastructure than SI-BONE. The company's moat rests on a body of clinical evidence that includes four randomised controlled trials and more than 190 peer-reviewed publications, accumulated over more than 150,000 procedures since 2009. That evidence base is difficult to replicate quickly and provides a credible differentiator when hospitals evaluate procedural platforms.
The raised guidance assumes gross margin holds near 79%, which management confirmed, and operating expense growth is now guided at approximately 12% rather than the 12.5% communicated in May. The company retained $145.9 million in cash and short-term investments at quarter end, providing adequate runway to fund the planned product launch and continued physician-adoption programmes without near-term dilutive financing. The net loss of $4.1 million, while still in the red, represents a 33.6% improvement year-on-year, and investors will be watching the Q4 launch and CMS reimbursement changes closely as twin catalysts for potential EBITDA inflection.